Could Veracyte Inc (NASDAQ:VCYT) Change Direction After Less Shorts?

March 14, 2018 - By Ellis Scott

 Could Veracyte Inc (NASDAQ:VCYT) Change Direction After Less Shorts?

Investors sentiment decreased to 1.76 in 2017 Q3. Its down 0.12, from 1.88 in 2017Q2. It fall, as 11 investors sold Veracyte, Inc. shares while 14 reduced holdings. 14 funds opened positions while 30 raised stakes. 22.46 million shares or 6.26% more from 21.14 million shares in 2017Q2 were reported.
Int Grp, New York-based fund reported 15,879 shares. Denver Advisors, Colorado-based fund reported 71,628 shares. Royal National Bank Of Canada stated it has 12,937 shares. Nationwide Fund Advsr invested in 13,235 shares. Parametric Portfolio Assoc Ltd Llc accumulated 87,036 shares. Panagora Asset Mngmt holds 0% in Veracyte, Inc. (NASDAQ:VCYT) or 108,774 shares. Bridgeway Cap Mgmt Inc has invested 0.04% of its portfolio in Veracyte, Inc. (NASDAQ:VCYT). Jpmorgan Chase And has invested 0% of its portfolio in Veracyte, Inc. (NASDAQ:VCYT). Mufg Americas Corporation holds 1,064 shares or 0% of its portfolio. The New York-based Tower Research Limited Company (Trc) has invested 0% in Veracyte, Inc. (NASDAQ:VCYT). Broadfin Lc, a New York-based fund reported 1.02 million shares. 274,294 were accumulated by Northern Trust. Rhumbline Advisers stated it has 25,119 shares or 0% of all its holdings. Bancorp Of Mellon has 0% invested in Veracyte, Inc. (NASDAQ:VCYT) for 72,459 shares. Wells Fargo And Mn accumulated 27,655 shares.

Since September 25, 2017, it had 0 insider buys, and 3 selling transactions for $381,180 activity. $50,624 worth of Veracyte, Inc. (NASDAQ:VCYT) shares were sold by Anderson Bonnie H.

The stock of Veracyte Inc (NASDAQ:VCYT) registered a decrease of 0.67% in short interest. VCYT’s total short interest was 737,500 shares in March as published by FINRA. Its down 0.67% from 742,500 shares, reported previously. With 131,400 shares average volume, it will take short sellers 6 days to cover their VCYT’s short positions. The short interest to Veracyte Inc’s float is 3.54%.

The stock decreased 2.35% or $0.15 during the last trading session, reaching $6.24. About 71,260 shares traded. Veracyte, Inc. (NASDAQ:VCYT) has risen 56.46% since March 14, 2017 and is uptrending. It has outperformed by 39.76% the S&P500.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States. The company has market cap of $213.98 million. The firm uses genomic technology to resolve diagnostic ambiguity. It currently has negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

Veracyte, Inc. (NASDAQ:VCYT) Ratings Coverage

Among 6 analysts covering Veracyte (NASDAQ:VCYT), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Veracyte had 11 analyst reports since August 14, 2015 according to SRatingsIntel. As per Tuesday, November 7, the company rating was downgraded by Janney Capital. The rating was downgraded by Piper Jaffray on Tuesday, November 7 to “Hold”. The firm has “Outperform” rating given on Tuesday, November 7 by Leerink Swann. Piper Jaffray maintained the stock with “Overweight” rating in Friday, August 14 report. The firm has “Buy” rating given on Friday, August 14 by BTIG Research. Cantor Fitzgerald initiated the shares of VCYT in report on Friday, December 18 with “Buy” rating. As per Tuesday, November 29, the company rating was upgraded by Janney Capital.

More news for Veracyte, Inc. (NASDAQ:VCYT) were recently published by:, which released: “Veracyte Announces New Data Demonstrating “Real-World” Performance of Afirma …” on March 14, 2018.‘s article titled: “Form 4 VERACYTE, INC. For: Mar 02 Filed by: Hall Christopher M” and published on March 06, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: